<code id='2162D837DA'></code><style id='2162D837DA'></style>
    • <acronym id='2162D837DA'></acronym>
      <center id='2162D837DA'><center id='2162D837DA'><tfoot id='2162D837DA'></tfoot></center><abbr id='2162D837DA'><dir id='2162D837DA'><tfoot id='2162D837DA'></tfoot><noframes id='2162D837DA'>

    • <optgroup id='2162D837DA'><strike id='2162D837DA'><sup id='2162D837DA'></sup></strike><code id='2162D837DA'></code></optgroup>
        1. <b id='2162D837DA'><label id='2162D837DA'><select id='2162D837DA'><dt id='2162D837DA'><span id='2162D837DA'></span></dt></select></label></b><u id='2162D837DA'></u>
          <i id='2162D837DA'><strike id='2162D837DA'><tt id='2162D837DA'><pre id='2162D837DA'></pre></tt></strike></i>

          Home / knowledge / focus

          focus


          focus

          author:hotspot    Page View:9848
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In